Skip to content

Is Mg do Improve the Glycemic Control in Patients Drink a Desalinate Water

Daily Intake of Magnesium From Drinking Water in Relation to Diabetes Mellites

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04632277
Acronym
Mg
Enrollment
102
Registered
2020-11-17
Start date
2020-08-25
Completion date
2021-08-01
Last updated
2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Glucose, High Blood, Patients

Keywords

Magnesium, Diabetes mellitus, Blood samples

Brief summary

Background and aim: Diabetes mellitus as a chronic disease is on rise on parallel with diseases. Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. We aim to present an overview of the possible influence of drinking water in general and mineral water in particular in improving glycemic parameters in persons with type 2 diabetes. Method: A randomized double blind controlled clinical trial will be conducted at the Endocrine clinic (KFHU) on 900 of patients with T2DM. All subjects participated in this study will be randomly allotted into three groups (each group N=300) to which the three waters were supplied in similar bottles marked A tap water, B bottle water and C control without any intervention. Blood samples will be taken before and after the intervention to determine the serum concentration of magnesium, Calcium, Vit D, creatinine, FBS, serum Ca, HbA1c, fasting C-peptide levels, fasting insulin levels and insulin sensitivity. Magnesium and calcium levels in urine will be expressed as the creatinine ratio

Detailed description

Study population and design: A randomized double blind controlled clinical trial will be conducted at the Endocrine clinic (KFHU) on 900 of patients with T2DM. This sample size was calculated at confidence interval of 95%. for the total diabetic outpatients in Endocrine clinic at KFHU during the period October 2020-May 2021. All subjects living in the 3 catchment areas (Dammam. Khobar and Dhahran) in the eastern province before inclusion were selected. Intervention All subjects participated in this study will be randomly (double-blind) allotted into three groups (each group N=300) to which the three waters were supplied in similar bottles marked A tap water, B Low Mg bottle water (50mg/l) and C high Mg bottle water (100 mg/l). These doses have been chosen according to the guideline of WHO. All patients will be asked to consume at least one liter of water/day. When preparing coffee and tea, ordinary tap water could be used. The intervention will be lasted for lasted 3 months. None of the participants will be changed their normal dietary habits during the trial. The mean values of all the studied parameters will be checked before starting the protocol for standardization of the protocol situp of the participants. Moreover, the diary magnesium intake will be calculated by a dietitian and all the influential factors such as, demographic factors, baseline 25(OH)D, Vit D and calcium intake, Oestrogen use and sun exposure will be controlled and monitored during the research. Inclusion criteria: All patients with type 2 on any diabetic treatment aged 20-85 years old with hypomagnesemia (less than 0.6 mmol/L (1.46 mg/dL). Exclusion criteria: Type 1 diabetic patients, pregnant women, patients who use of immunosuppressive, corticosteroids, and non-steroidal anti-inflammatory, patients who have renal dysfunction or doing dialysis, Sampling and data collection: All participants will be seated in air-conditioned rooms and had 10-15 min of rest before measurements were taken. After signing the consent form, the demographic and clinical data of all subjects will be record including: address, education level, smoking, age, sex; and body weight and height were measured to calculate body mass index (BMI). The average of three consecutive blood pressure readings with intervals of 5-min rest will be obtained, using an electronic sphygmomanometer. All measurements and indicators will be taken at the base line and after three months of intervention. Blood and urine samples Blood samples will be taken before and after the intervention to determine the serum concentration of serum magnesium, Calcium, Phosphorus, Vit D, creatinine, Urea, Lipid profile, Uric acid, Liver function test, Fasting blood glucose, HbA1c, fasting C-peptide levels, fasting insulin levels and insulin sensitivity. The HOMA-IR will be calculated according to the following formulas: HOMA-IR = (glucose mg x insulin level)/405. Blood samples will be collected before and after the intervention period. A sample of urine will be collected to measure Microalbuminuria. The analysis will be performed at the central laboratory, KFHU. Research ethics: Ethical approved and performed under the guideline of the research ethics committee of Imam Abdulrahman Bin Faisal University, Saudi Arabia and written consent will be obtained from all subjects. Statistical analysis: The data was entered into an SPSS. The data analysis will be divided into two steps: Descriptive statistics and analysis of variance. The quantitative data will be represented in the form of proportions (%) and of means with standard deviations. The one-way ANOVA will be used to measure the changes between groups. Funds details: This project will be supported by The Saline Water Conversion Corporation Research Institute at Al-Jubail, KSA.

Interventions

OTHERWater

Participants will receive a tab water

DIETARY_SUPPLEMENTWater with low Mg

Participants will receive Low Mg bottle water (50mg/l)

DIETARY_SUPPLEMENTWater with high Mg

Participants will receive High Mg bottle water (100mg/l)

Sponsors

The Saline Water Conversion Corporation Research Institute at Al-Jubail, KSA.
CollaboratorUNKNOWN
Imam Abdulrahman Bin Faisal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* All patients with type 2 * On any diabetic treatment

Exclusion criteria

* Type 1 diabetic Delete repeated word * Pregnant women * Patients who use of immunosuppressive, corticosteroids, and non-steroidal anti-inflammatory. * Patients who have renal dysfunction or doing dialysis.

Design outcomes

Primary

MeasureTime frameDescription
Serum Cholesterol3 monthsSerum Cholesterol mg/dL. Baseline and 3 months
Magnesium (Mg).3 monthsSerum Mg mg/dL. Baseline and 3 months
Fasting blood glucose3 monthsFasting blood glucose mg/dL. Baseline and 3 months
Insulin μIU/mL3 monthsSerum Insulin μIU/mL. Baseline and 3 months
HbA1c3 monthsHbA1c. Baseline and 3 months
Serum HDL (high-density lipoprotein)3 monthsSerum HDL mg/dL. Baseline and 3 months
Serum LDL (low-density lipoprotein)3 monthsSerum LDL mg/dL. Baseline and 3 months
Serum Triglycerides3 monthsSerum Triglycerides mg/dL. Baseline and 3 months

Secondary

MeasureTime frameDescription
Serum Creatinine.3 monthsBaseline and 3 months (mg/dL)
Urine Microalbumin3 monthsmicroalbuminurea (30-300 mcg/mg creatinine). Baseline and 3 months
Serum Vitamin D3 monthsVit D ng/mL. Baseline and 3 months
Blood Urea mg/dL3 monthsBaseline and 3 months
Serum Calcium3 monthsCa md/dL. Baseline and 3 months

Other

MeasureTime frameDescription
Body height3 monthsheight in meters. Baseline and 3 months
Body mass index3 monthsWeight in kilograms divided by the square of height in meters. Baseline and 3 months
Body weight3 monthsweight in kilograms. Baseline and 3 months

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026